APGE — Apogee Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Abbvie To Acquire Apogee Therapeutics, Deepening Immunology Portfolio
Factbox: Major deals involving US drugmakers and biotechs over the past decade
NASDAQ RESUMED AT 07:20 AM
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)
AbbVie strikes $10.9 billion deal for Apogee Therapeutics
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Apogee Therapeutics soars on report Abbvie nearing $11 bln buyout deal
AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
Brief: Abbvie Closes In On Nearly $11Bn Deal For Biotech Apogee Therapeutics - FT
U.S. RESEARCH ROUNDUP-Salesforce, Snowflake, Zscaler
Apogee secures up to $1.3 billion from Blackstone to advance eczema drug (updated)
U.S. STOCKS ON THE MOVE-Boston Scientific, Banc of California, Salesforce
U.S. STOCKS ON THE MOVE-UnitedHealth, Astrotech, Boston Scientific
Apogee reports skin disease therapy mid-stage trial results; shares fall
Brief: Apogee Therapeutics Inc - Blackstone Life Sciences To Pay $100 Million Upfront For Revenue Share On Zumilokibart Sales - SEC Filing
Brief: Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration With Blackstone Life Sciences To Advance Phase 3 Development And Commercialization Of Zumilokibart
Brief: Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results From Phase 2 Apex Trial Of Zumilokibart In Moderate-To-Severe Atopic Dermatitis
U.S. STOCKS ON THE MOVEd-Micron, Abercrombie & Fitch, Q32 Bio
Apogee secures up to $1.3 billion from Blackstone to advance eczema drug